We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest trading session, Pfizer (PFE - Free Report) closed at $32.75, marking a -1.56% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.01%. At the same time, the Dow added 0.04%, and the tech-heavy Nasdaq lost 0.25%.
Prior to today's trading, shares of the drugmaker had lost 1.1% over the past month. This has was narrower than the Medical sector's loss of 2.91% and the S&P 500's loss of 1.6% in that time.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 31, 2023. In that report, analysts expect Pfizer to post earnings of $0.59 per share. This would mark a year-over-year decline of 66.85%. Meanwhile, the latest consensus estimate predicts the revenue to be $14.43 billion, indicating a 36.27% decrease compared to the same quarter of the previous year.
Any recent changes to analyst estimates for Pfizer should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.84% lower. Pfizer currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 10. Its industry sports an average Forward P/E of 14.14, so one might conclude that Pfizer is trading at a discount comparatively.
Also, we should mention that PFE has a PEG ratio of 1.11. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.84 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 240, positioning it in the bottom 5% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Pfizer (PFE - Free Report) closed at $32.75, marking a -1.56% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.01%. At the same time, the Dow added 0.04%, and the tech-heavy Nasdaq lost 0.25%.
Prior to today's trading, shares of the drugmaker had lost 1.1% over the past month. This has was narrower than the Medical sector's loss of 2.91% and the S&P 500's loss of 1.6% in that time.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 31, 2023. In that report, analysts expect Pfizer to post earnings of $0.59 per share. This would mark a year-over-year decline of 66.85%. Meanwhile, the latest consensus estimate predicts the revenue to be $14.43 billion, indicating a 36.27% decrease compared to the same quarter of the previous year.
Any recent changes to analyst estimates for Pfizer should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.84% lower. Pfizer currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 10. Its industry sports an average Forward P/E of 14.14, so one might conclude that Pfizer is trading at a discount comparatively.
Also, we should mention that PFE has a PEG ratio of 1.11. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.84 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 240, positioning it in the bottom 5% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.